UK regulator approves second Alzheimer's drug in months but government won't pay for it

1 month ago 7
ARTICLE AD BOX
Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers
Read Entire Article
  1. Homepage
  2. World News
  3. UK regulator approves second Alzheimer's drug in months but government won't pay for it

Related

Israel says 7 injured after Hezbollah launches massive rocket, projectile volley

Israel says 7 injured after Hezbollah launches massive rocke...

18 minutes ago 1
Colorado Civil Air Patrol plane crash kills pilot and photographer, one injured

Colorado Civil Air Patrol plane crash kills pilot and photog...

40 minutes ago 1
News24 | Six dead, 10 wounded in Mexico bar shooting

News24 | Six dead, 10 wounded in Mexico bar shooting

59 minutes ago 1
RIGHT SIDEBAR TOP AD

Trending

1. Leganés Real Madrid
2. Commanders
3. Max Verstappen
4. Ohio State game
5. SEC Championship Game
6. Chuck Woolery
7. USC vs UCLA
8. Auburn football
9. Nuggets vs Lakers
10. Alabama football

Popular

Epstein Survivor Claims She Was Paid $15,000 To Have Sex With UK Royal

Epstein Survivor Claims She Was Paid $15,000 To Have Sex Wit...

10 months ago 979
Ex Australian Advertising Executive Set To Become Queen Of Denmark

Ex Australian Advertising Executive Set To Become Queen Of D...

10 months ago 809
Video Of New Zealand Politician's Powerful Speech Goes Viral

Video Of New Zealand Politician's Powerful Speech Goes Viral...

10 months ago 681
One Of Palaeontology's Biggest Mysteries Solved - The Giant Ape Extinction

One Of Palaeontology's Biggest Mysteries Solved - The Giant ...

10 months ago 584
Amid Row With India, Maldives President Praises China's Belt & Road Plan

Amid Row With India, Maldives President Praises China's Belt...

10 months ago 459
RIGHT SIDEBAR BOTTOM AD
English (US) English (US)
About Us · Contact Us · Terms & Conditions ·

© MidnightSun 2024. All rights are reserved